Johnson is a medical oncologist whose research focus is new drug development for patients with lung cancer. In 2021, Dr. Johnson assumed the role of director of the Lung Cancer Research Program for Sarah Cannon Research Institute, where she supervises the lung cancer clinical trial portfolio across the Sarah Cannon network. Johnson is the co-leader of the Immune Effector Cell Therapies program, and has directed the development of the Solid Tumor Cellular Therapy program in the Drug Development Unit in Nashville. Prior to joining Sarah Cannon, Johnson was an Associate Professor at Northwestern University and Feinberg School of Medicine She earned her medical degree from the University of Pennsylvania. After completing residency in internal medicine at New York Hospital/Weill Cornell Medical Center, she did her fellowship training at Memorial Sloan Kettering Cancer Center where she served one year as chief fellow. She is board certified in internal medicine and medical oncology.